A diagnostic imaging tool that measures the persistent reduction in connectivity between the anterior hippocampus and the default mode network to quantify the therapeutic 'window' of psychedelic treatment.
The SWOT analysis reveals a high-value clinical utility that transforms subjective psychedelic experiences into objective biomarkers, though it faces significant scaling hurdles due to MRI dependency. The idea's success depends on transitioning from a research-grade tool to a standardized diagnostic protocol accepted by regulatory bodies.
Strengths3
Weaknesses3
Opportunities3
Threats3
This framework helps evaluate the internal technical strength of the biomarker approach against the external opportunity of the growing personalized psychiatry market. · Generated 2026-09-07 by cavi/gemma4-31b-it-awq-4bit-32kAI-generated